{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:30Z","timestamp":1763132670396,"version":"3.45.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To examine the association between gout and subsequent development and progression of age-related macular degeneration (AMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective cohort study, a multicenter health care research network was used to identify patients with an International Classification of Diseases, 10th Revision for idiopathic gout and a prescription for uric acid\u2013lowering agent (Gout cohort) compared with a matched cohort of patients without a diagnosis of gout (Control cohort) for ophthalmic outcomes. Propensity score matching was applied to balance baseline demographics and health status between cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients with gout had an increased risk of developing dry AMD (relative risk, 2.73, 95% confidence intervals, 2.30\u20133.25;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), advanced dry AMD (relative risk, 2.64, 95% confidence intervals, 1.32\u20135.28;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), wet AMD (relative risk, 2.48, 95% confidence intervals, 1.82\u20133.38;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and needing subsequent antivascular endothelial growth factor therapy (relative risk, 2.80, 95% confidence intervals, 2.14\u20133.67;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) compared with those without gout at 5 years. Similar trends were observed among patients with early AMD and gout compared with those with early AMD without gout.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In a national multicenter database, an increased risk of AMD development and progression to advanced disease stages was found among patient with gout compared with controls. Additional investigation into the mechanisms and effects of hyperuricemia are necessary to clarify these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004604","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T20:00:12Z","timestamp":1752091212000},"page":"2289-2296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["GOUT AND RISK OF AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"45","author":[{"given":"Ahmed M.","family":"Alshaikhsalama","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Wai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euna","family":"Koo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Byers Eye Institute, Horngren Family Vitreoretinal Center, Stanford University School of Medicine, Palo Alto, California; and"},{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","article-title":"Prevalence of age-related macular degeneration in the US in 2019","volume":"140","author":"Rein","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/opo.12675","article-title":"Risk factors for progression of age-related macular degeneration","volume":"40","author":"Heesterbeek","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/IAE.0000000000000338","article-title":"Metabolic syndrome and risk of age-related macular degeneration","volume":"35","author":"Ghaem Maralani","year":"2015","journal-title":"Retina"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1001\/jamaophthalmol.2024.1822","article-title":"Melatonin and risk of age-related macular degeneration","volume":"142","author":"Jeong","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamaophthalmol.2024.4400","article-title":"Curcuma-based nutritional supplements and risk of age-related macular degeneration","volume":"142","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.21238","article-title":"Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation","volume":"52","author":"Liu-Bryan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12886-018-0669-6","article-title":"Retinal complications of gout: a case report and review of the literature","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","article-title":"Inflammation and its role in age-related macular degeneration","volume":"73","author":"Kauppinen","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"R13-20251114","first-page":"581695","article-title":"Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction","volume":"2012","author":"Kurihara","year":"2012","journal-title":"Int J Inflam"},{"key":"R14-20251114","first-page":"36","article-title":"Serum uric acid levels and its association with age-related macular degeneration (ARMD)","volume":"65","author":"Subramani","year":"2010","journal-title":"Med J Malaysia"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"10142","DOI":"10.3390\/ijerph191610142","article-title":"Gout as a risk factor for age-related macular degeneration in Taiwanese adults-A population-based study in taiwan","volume":"19","author":"Hsu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"e0199562","DOI":"10.1371\/journal.pone.0199562","article-title":"Gout and the risk of age-related macular degeneration in the elderly","volume":"13","author":"Singh","year":"2018","journal-title":"PLos One"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLos Med"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R19-20251114","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"key":"R21-20251114","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.2.1247.995","article-title":"The bowman lecture on the relation of certain diseases of the eye to gout","volume":"2","author":"Hutchinson","year":"1884","journal-title":"Br Med J"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.bbrc.2018.06.097","article-title":"The role of uric acid in the pathogenesis of diabetic retinopathy based on notch pathway","volume":"503","author":"Zhu","year":"2018","journal-title":"Biochem Biophy Res Commun"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/bjo.20.9.510","article-title":"Inflammatory disease in the eye caused by gout","volume":"20","author":"Wood","year":"1936","journal-title":"Br J Ophthalmol"},{"key":"R24-20251114","first-page":"632","article-title":"Ocular abnormalities in patients with gout","volume":"17","author":"Ferry","year":"1985","journal-title":"Ann Ophthalmol"},{"key":"R25-20251114","first-page":"3720","article-title":"Attributable risk estimates for cataract to prioritize medical and public health action","volume":"41","author":"McCarty","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-20251114","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/s41433-021-01456-7","article-title":"The need to investigate hyperuricemia as a factor in the onset of age-related macular degeneration","volume":"35","author":"Pai","year":"2021","journal-title":"Eye (Lond)."},{"key":"R27-20251114","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1167\/iovs.12-10655","article-title":"NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration","volume":"54","author":"Tseng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R28-20251114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.preteyeres.2017.03.002","article-title":"The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD","volume":"60","author":"Datta","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"R29-20251114","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2013.7671","article-title":"Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study","volume":"132","author":"Klein","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R30-20251114","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm1709","article-title":"Oxidative damage-induced inflammation initiates age-related macular degeneration","volume":"14","author":"Hollyfield","year":"2008","journal-title":"Nat Med"},{"key":"R31-20251114","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/archopht.121.5.674","article-title":"Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy","volume":"121","author":"Klein","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R32-20251114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/RHU.0000000000000246","article-title":"An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements","volume":"21","author":"Singh","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"R33-20251114","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3949\/ccjm.69.8.594","article-title":"Asymptomatic hyperuricemia: to treat or not to treat","volume":"69","author":"Dincer","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"R34-20251114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.63.10.8","article-title":"Short-term hyperuricemia leads to structural retinal changes that can be reversed by serum uric acid lowering agents in mice","volume":"63","author":"Pai","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-20251114","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/TCRM.S162956","article-title":"Improving adherence to gout therapy: an expert review","volume":"14","author":"Perez-Ruiz","year":"2018","journal-title":"Ther Clin Risk Manag"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:00:56Z","timestamp":1763132456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004604","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}